Patient Characteristics and Risk Factors in Invasive Mold Infections: Comparison from a Systematic Review and Database Analysis

References

• Harpaz R, Dahl R, Dooling K. The Prevalence of Immunocompromised Adults: United States, 2013. Oxford University Press; 2016.
   Google Scholar
• Krcmery V, Kunova E, Jesenska Z, et al. Invasive mold infections in cancer patients: 5 years’ experience withAspergillus, Mucor, Fusarium andAcremonium infections. Support Care Cancer. 1996;4(1):39–45. doi:10.1007/BF01769874
   Web of Science ®Google Scholar
• Kriengkauykiat J, Ito JI, Dadwal S. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3(1):175–191. doi:10.2147/CLEP.S12502
   Google Scholar
• Omrani AS, Almaghrabi RS. Complications of hematopoietic stem transplantation: fungal infections. Hematol Oncol Stem Cell Ther. 2017;10(4):239–244. doi:10.1016/j.hemonc.2017.05.013
   PubMedGoogle Scholar
• Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65. doi:10.1007/978-1-4939-6515-1_2
   PubMedGoogle Scholar
• Schauwvlieghe A, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–792. doi:10.1016/s2213-2600(18)30274-1
   PubMed Web of Science ®Google Scholar
• Apostolopoulou A, Esquer Garrigos Z, Vijayvargiya P, Lerner AH, Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic Review of the literature. Diagnostics (Basel). 2020;10(10):807. doi:10.3390/diagnostics10100807
   Google Scholar
• Anastasopoulou A, DiPippo AJ, Kontoyiannis DP. Non-Aspergillus invasive mould infections in patients treated with ibrutinib. Mycoses. 2020;63(8):787–793. doi:10.1111/myc.13120
   PubMed Web of Science ®Google Scholar
• Vallabhaneni S, Benedict K, Derado G, Mody RK. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000–2013. Open Forum Infect Dis. 2017;4(1). doi:10.1093/ofid/ofw268
   Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43(Suppl s1):S49–58. doi:10.1080/13693780400020113
   Web of Science ®Google Scholar
• Sinkó J, Csomor J, Nikolova R, et al. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis. 2008;10(2):106–109. doi:10.1111/j.1399-3062.2007.00264.x
   Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653. doi:10.1086/432579
   PubMed Web of Science ®Google Scholar
• Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–1867. doi:10.1111/j.1469-0691.2010.03456.x
   PubMed Web of Science ®Google Scholar
• Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J Antimicrob Chemother. 2017;72(suppl_1):i39–i47. doi:10.1093/jac/dkx032
   Web of Science ®Google Scholar
• Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol. 2011;49(S1):S7–S12. doi:10.3109/13693786.2010.505204
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97(6):1604–1610. doi:10.1182/blood.v97.6.1604
   PubMed Web of Science ®Google Scholar
• Latgé JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12(2):310–350.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis. 2000;31(1):188–189. doi:10.1086/313918
   PubMed Web of Science ®Google Scholar
• von Lilienfeld-toal M, Wagener J, Einsele H, Cornely OA, Kurzai O. Invasive fungal infection. Dtsch Arztebl Int. 2019;116(16):271–278. doi:10.3238/arztebl.2019.0271
   PubMed Web of Science ®Google Scholar
• Dignani MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000Prime Rep. 2014;6:81. doi:10.12703/p6-81
   PubMedGoogle Scholar
• Winters B, Custer J, Galvagno SM Jr., et al. Diagnostic errors in the intensive care unit: a systematic review of autopsy studies. BMJ Qual Saf. 2012;21(11):894–902. doi:10.1136/bmjqs-2012-000803
   PubMed Web of Science ®Google Scholar
• Donnelley MA, Zhu ES, Thompson GR 3rd. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79–86. doi:10.2147/IDR.S81416
   PubMed Web of Science ®Google Scholar
• Ashley ESD, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of Systemic Antifungal Agents. Clin Infect Dis. 2006;43(Supplement_1):S28–S39. doi:10.1086/504492
   Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 Years of Clinical Experience. Rev Infect Dis. 1990;12(2):308–329. doi:10.1093/clinids/12.2.308
   PubMedGoogle Scholar
• Label. CFP. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf. Accessed November 20, 2020.
   Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784. doi:10.7326/m14-2385
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med. 1993;32(05):382–387. doi:10.1055/s-0038-1634956
   Google Scholar
• Wessolossky M, Welch VL, Sen A, Babu TM, Luke DR. Invasive Aspergillus infections in hospitalized patients with chronic lung disease. Infect Drug Resist. 2013;6:33–39. doi:10.2147/IDR.S43069
   Google Scholar
• Zhang XY, Yang M, Hu J, Zhao H, Li L. Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: clinical presentation, risk factors, and outcomes. J Int Med Res. 2018;46(2):819–827. doi:10.1177/0300060517729907
   Web of Science ®Google Scholar
• Amsden JR, Slain D. Dosing antifungals in obesity: a literature review. Curr Fungal Infect Rep. 2019;13(1):21–32. doi:10.1007/s12281-019-0335-3
   Web of Science ®Google Scholar
• Pfizer. VFEND (voriconazole) Prescribing Information. New York, NY. 2019.
   Google Scholar
• Astellas Pharma US I. AmBisome (amphotericin B) liposome for injection - Prescribing Information. Northbrook, IL. 2019.
   Google Scholar
• Co M. Noxafil (posaconazole) Prescribing Information. Whitehouse Station, NJ 2020.
   Google Scholar
• Astellas Pharma US I. CRESEMBA (isavuconazonium sulfate) Prescribing Information. Northbrook, IL 2019.
   Google Scholar
• Desai A, Kovanda L, Andes DR, et al. No Dose Adjustment Necessary for Isavuconazole in Obese Patients. Oxford University Press; 2016.
   Google Scholar
• Desai AVK, Kovanda L, Hope WW, et al. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. Antimicrob Agents Chemother. 2017;61(12):12. doi:10.1128/AAC.01034-17
   Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46(3):327–360. doi:10.1086/525258
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405–e421. doi:10.1016/s1473-3099(19)30312-3
   PubMed Web of Science ®Google Scholar
• Kennedy KJD, Slavin MA, van Hal SJ, et al. Mucormycosis in Australia: contemporary epidemiology and outcomes. Clin Microbiol Infect. 2016;22(9):775–781. doi:10.1016/j.cmi.2016.01.005
   PubMed Web of Science ®Google Scholar
• Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates. PLoS One. 2017;12(6):e0179136. doi:10.1371/journal.pone.0179136
   PubMed Web of Science ®Google Scholar